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The World Health Organization (WHO) 
has announced its third global patient 
safety challenge,1 which aims to re-
duce the global burden of iatrogenic 
medication-related harm by 50% within 
five years. The intention is to match 
the global reach and impact of the two 
earlier global patient safety challenges: 
Clean care is safer care and Safe sur-
gery saves lives.2,3 The third challenge, 
Medication without harm, invites health 
ministers to initiate national plans ad-
dressing four domains of medication 
safety: engaging patients and the pub-
lic; medication as products; education, 
training and monitoring of health-care 
professionals; and systems and practices 
of medication management. This chal-
lenge also commits WHO to using its 
convening and coordinating powers to 
drive forward a range of global actions 
on medication safety.4
Here, we focus on three priority 
areas of medication safety that most af-
fect patients, just as hand hygiene and 
the surgical checklist were chosen as 
the flagships of the first two challenges. 
These three areas are high-risk situa-
tions, polypharmacy and transitions of 
care. Each area is associated with a sub-
stantial burden of harm and therefore, 
if appropriately managed, could reduce 
the risk of harm to many patients.
Certain classes of medications are 
particularly liable to produce adverse 
reactions. They tend to have a narrow 
therapeutic index, meaning that small 
dosing errors can cause catastrophic 
outcomes. For example, the use of war-
farin for anticoagulation is a high-risk 
clinical situation involving a medica-
tion because its use carries associated 
risks of bleeding if the international 
normalized ratio is too high and risks 
of further thrombosis if it is too low. 
The Clinical Excellence Commission 
has summarized high-risk medications 
in the acronym A PINCH (anti-infective 
agents; potassium and other electrolytes; 
insulin; narcotics and other sedatives; 
chemotherapeutic and immunosup-
pressive agents and heparin and antico-
agulants).5 However, this classification 
is not exhaustive; for example, other 
medications carry risks for those with 
underlying diseases, such as chronic 
kidney disease. Focusing on certain key 
classes of medications has enabled in-
vestigators to develop interventions that 
reduce inadvertent harm caused by these 
medications. Such interventions can 
involve low-technology solutions, such 
as patient medication diaries, or harness 
the potential of digital technology, as 
with clinical decision support systems 
linked with electronic health records.6
As people tend to live longer, receive 
treatment for more than one condition 
at a time and have access to an increas-
ing number of therapeutic options, they 
tend to take multiple medications. This 
intake increases the likelihood of drug 
interactions. Elderly patients may also 
find it difficult to adhere to complex 
regimens, increasing the likelihood of 
patient-induced errors. Progress has 
been made in identifying medication 
history and drug-drug combinations 
that are particularly problematic, en-
abling risk-stratification and risk-reduc-
tion approaches through, for example, 
de-prescribing initiatives in Canada7 
and the United States of America.8 How-
ever, these initiatives are only addressing 
a part of the problem of polypharmacy.
Reducing medication-related harm 
in the field of transitions of care9 is the 
third priority area. Failure to effectively 
communicate information on medicines 
and/or underlying risk factors may cause 
medication errors when patients move 
between care settings (e.g. from primary 
to hospital care) and/or between care 
providers within the same setting (e.g. 
from out-patient respiratory to out-pa-
tient cardiovascular clinics). Initiatives 
designed to improve communication 
across such boundaries include standard 
operating procedures to support medi-
cation reconciliation such as WHO’s 
High 5s Project,10 pharmacist review of 
patients following admission and dis-
charge from hospitals, summary of care 
records detailing principal diagnoses, 
allergies and medication(s), and shared 
cloud-based applications and electronic 
health records.
The three early priorities of the 
third global patient safety challenge are 
not mutually exclusive; many patients 
may be exposed to risks from a combina-
tion of adverse reactions, polypharmacy 
and miscommunication. Health-care 
professionals should focus particularly 
on those patients who are at higher risk 
of death or serious illness because of 
medication-related harm.
Making progress across these areas 
will require politicians and health-
care leaders to prioritize medication 
safety – as was achieved in the first 
two challenges. The context in which 
medication-related harm occurs across a 
range of care settings needs to be clearly 
understood. Implementing measures to 
reduce this harm will need to include 
educating and empowering patients 
and carers; developing tools to assist 
frontline health-care professionals; 
and engineering new systems of care to 
create resilience against the factors that 
predispose to the risk of medication 
errors. ■
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